Peptide targeting of tumor lymph vessels

Annals of the New York Academy of Sciences

Volumn 1131, Issue , 2008, Pages 37-43

  Laakkonen, Pirjo ^a   Zhang, Lianglin ^b   Ruoslahti, Erkki ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Lymphatics; Peptide; Phage display; Tumor targeting

Indexed keywords

CANCER STAGING; CELL TYPE; CONFERENCE PAPER; ENDOTHELIUM CELL; IN VIVO STUDY; LYMPH VESSEL; LYMPHANGIOMA; MELANOMA; PROTEIN TARGETING; TARGET CELL; TARGET ORGAN; TUMOR CELL; TUMOR GROWTH;

EID: 44449120249     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1413.003     Document Type: Conference Paper

References (48)

1. Holash, J., P.C. Maisonpierre, D. Compton, et al. 1999. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 : 1994 1998.
2. Coussens, L.M., D. Hanahan & J.M. Arbeit. 1996. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am. J. Pathol. 149 : 1899 1917.
3. Hattori, K., S. Dias, B. Heissig, et al. 2001. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193 : 1005 1014.
4. Rafii, S. 2000. Circulating endothelial precursors: mystery, reality, and promise [comment]. J. Clin. Invest. 105 : 17 19.
5. McDonald, D.M. & A.J. Foss. 2000. Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metast. Rev. 19 : 109 120.
6. Carmeliet, P. & R.K. Jain. 2000. Angiogenesis in cancer and other diseases. Nature 407 : 249 257.
7. Ruoslahti, E. 2002. Specialization of tumour vasculature. Nat. Rev. Cancer. 2 : 83 90.
8. St. Croix, B., C. Rago, V. Velculescu, et al. 2000. Genes expressed in human tumor endothelium [see comments]. Science 289 : 1197 1202.
9. Oh, P., Y. Li, J. Yu, et al. 2004. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy [see comment]. Nature 429 : 629 635.
10. Ribatti, D., B. Nico, A. Vacca, et al. 2002. Endothelial cell heterogeneity and organ specificity. J. Hematother. Stem Cell Res. 11 : 81 90.
11. Zhang, L., J.A. Hoffman & E. Ruoslahti. 2005. Molecular profiling of heart endothelial cells. Circulation 112 : 1601 1611.
12. Arap, W., W. Haedicke, M. Bernasconi, et al. 2002. Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. USA 99 : 1527 1531.
13. Rajotte, D., W. Arap, M. Hagedorn, et al. 1998. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest. 102 : 430 437.
14. Pasqualini, R. & E. Ruoslahti. 1996. Organ targeting in vivo using phage display peptide libraries. Nature 380 : 364 366.
15. Gerlag, D.M., E. Borges, P.P. Tak, et al. 2001. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res. 3 : 357 361.
16. Porkka, K., P. Laakkonen, J.A. Hoffman, et al. 2002. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. USA 99 : 7444 7449.
17. Laakkonen, P., K. Porkka, J.A. Hoffman, et al. 2002. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8 : 751 755.
18. Pasqualini, R., E. Koivunen & E. Ruoslahti. 1997. Alpha v integrins as receptors for tumor targeting by circulating ligands [see comments]. Nat. Biotechnol. 15 : 542 546.
19. Burg, M.A., R. Pasqualini, W. Arap, et al. 1999. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res. 59 : 2869 2874.
20. Joyce, J.A., P. Laakkonen, M. Bernasconi, et al. 2003. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 4 : 393 403.
21. Hoffman, J.A., E. Giraudo, M. Singh, et al. 2003. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell. 4 : 383 391.
22. Saharinen, P., T. Tammela, M.J. Karkkainen, et al. 2004. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 25 : 387 395.
23. Mattila, M.M., J.K. Ruohola, T. Karpanen, et al. 2002. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int. J. Cancer. 98 : 946 951.
24. Skobe, M., T. Hawighorst, D.G. Jackson, et al. 2001. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis [see comments]. Nat. Med. 7 : 192 198.
25. Mandriota, S.J., L. Jussila, M. Jeltsch, et al. 2001. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20 : 672 682.
26. Karpanen, T., M. Egeblad, M.J. Karkkainen, et al. 2001. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61 : 1786 1790.
27. Stacker, S.A., C. Caesar, M.E. Baldwin, et al. 2001. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics [see comments]. Nat. Med. 7 : 186 191.
28. Lin, J., A.S. Lalani, T.C. Harding, et al. 2005. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 65 : 6901 6909.
29. He, Y., K. Kozaki, T. Karpanen, et al. 2002. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling [see comments]. J. Natl. Cancer Inst. 94 : 819 825.
30. Podgrabinska, S., P. Braun, P. Velasco, et al. 2002. Molecular characterization of lymphatic endothelial cells [erratum appears in Proc. Natl. Acad. Sci. USA 2003 Apr 15;100(8):4970]. Proc. Natl. Acad. Sci. USA 99 : 16069 16074.
31. Petrova, T.V., T. Makinen, T.P. Makela, et al. 2002. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J. 21 : 4593 4599.
32. Kriehuber, E., S. Breiteneder-Geleff, M. Groeger, et al. 2001. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages [see comments]. J. Exp. Med. 194 : 797 808.
33. Hoffman, J.A., P. Laakkonen, K. Porkka, et al. 2004. In vivo and ex vivo selections using phage-displayed libraries. In Phage Display. T. Clackson & H.B. Lowman, Eds 171 192. Oxford University Press. Oxford, UK.
34. Prevo, R., S. Banerji, D.J. Ferguson, et al. 2001. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J. Biol. Chem. 276 : 19420 19430.
35. Jackson, D.G., R. Prevo, S. Clasper, et al. 2001. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol. 22 : 317 321.
36. Breiteneder-Geleff, S., A. Soleiman, H. Kowalski, et al. 1999. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 154 : 385 394.
37. Laakkonen, P., M.E. Akerman, H. Biliran, et al. 2004. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Natl. Acad. Sci. USA 101 : 9381 9386.
38. Langel, U. 2006. Handbook of Cell-Penetrating Peptides, 2nd ed. U. Langel, Ed. CRC Press (Taylor & Francis). Boca Raton, FL New York.
39. Ruoslahti, E., T. Duza & L. Zhang. 2005. Vascular homing peptides with cell-penetrating properties. Curr. Pharm. Des. 11 : 3655 3660.
40. Laakkonen, P. & E. Ruoslahti. 2006. Selective delivery to vascular addresses: in vivo applications of cell-type-specific cell-penetrating peptides. In Handbook of Cell-Penetrating Peptides. U. Langel, Ed 413 422. CRC Press (Taylor & Francis). Boca Raton, FL New York.
41. Zhang, L., E. Giraudo, J.A. Hoffman, et al. 2006. Lymphatic zip codes in premalignant lesions and tumors [erratum appears in Cancer Res.] Cancer Res. 66 : 5696 5706.
42. Akerman, M.E., W.C. Chan, P. Laakkonen, et al. 2002. Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. USA 99 : 12617 12621.
43. Rae, J.M.C., C.J. Meck, J.M. Haddad, B.R. Johnson, M.D. 2007. MDA-MB-435 cells are derived from M14 melanoma cells: a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat. 104 : 13 19.
44. Rae, J.M., S.J. Ramus, M. Waltham, et al. 2004. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin. Exp. Met. 21 : 543 552.
45. Greenberg, N.M., F. DeMayo, M.J. Finegold, et al. 1995. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92 : 3439 3443.
46. Ellerby, H.M., W. Arap, L.M. Ellerby, et al. 1999. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5 : 1032 1038.
47. Yi, M. & E. Ruoslahti. 2001. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc. Natl. Acad. Sci. USA 98 : 620 624.
48. Pasqualini, R., S. Bourdoulous, E. Koivunen, et al. 1996. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat. Med. 2 : 1197 1203.